Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma: Key Takeaways
March 25th 2022Rana McKay, MD, and Tom Powles, MBBS, MRCP, MD, highlight key data from the CLEAR trial and offer their overall opinions on the combination of lenvatinib plus pembrolizumab for the treatment of renal cell carcinoma [RCC].
Merseburger Discusses Future Research of PRESIDE Trial Enzalutamide Combo
March 23rd 2022Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.